Patrys publishes PAT-SM6 trial results

Patrys limited (ASX:PAB) has published the results of a phase I clinical trial of its anti-tumour antibody, PAT-SM6.

The patients enrolled in the safety and tolerability trial of the treatment demonstrated no significant adverse effects during infusion, immediately following dosing or at one-month follow up.

Analysis of blood samples collected in the trial also show that no patient generated a significant adverse immune response to the antibody.

One of the patients enrolled in the study showed increased cancer cell death following dosing.

The results have been published on schedule, following the successful completion of the trial last month.

According to Melbourne-based Patrys, pharmacokinetic parameters recorded in the trial will be used to inform the next planned clinical trial of PAT-SM6, in patients suffering from multiple myeloma.

This trial will be conducted at the University of Würzburg, Germany over a 12-month period, and is due to commence in April.

The company has also recently completed a multi-dose animal toxicology trial, in which subjects received dosages many times the maximum therapeutic dose. Animals in the trial demonstrated no significant adverse effects.

Patrys raised funds for these trials – as well as preclinical development of another potential cancer treatment antibody – with a $3.4 million placement in December.

Patrys (ASX:PAB) shares grew 2.78% in Tuesday's trading to $0.037 after the results were published.